180
- de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn’s disease:
long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353–8. - Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with inflix-
imab in pediatric- onset Crohn’s disease: a population-based study. Inflamm Bowel Dis.
2011;17:2144–52. - Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy
in children with Crohn’s disease. Inflamm Bowel Dis. 2009;15:816–22. - Grover Z, Biron R, Carman N, Lewindon P. Predictors of response to infliximab in children
with luminal Crohn’s disease. J Crohns Colitis. 2014;8:739–46. - Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab
therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr.
2014;59:758–62. - Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent peri-
anal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009;49:183–90. - Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration
in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2003;18:425–31. - Dupont-Lucas C, Dabadie A, Alberti C, Ruemmele FM. Predictors of response to infliximab in
paediatric perianal Crohn’s disease. Aliment Pharmacol Ther. 2014;40:917–29. - de Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. Diagnosis and treatment
of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr
Gastroenterol Nutr. 2013;57:401–12. - Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a
novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002;34:307–11. - Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric
ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298–301. - Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcer-
ative colitis. Inflamm Bowel Dis. 2005;11:213–8. - McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin
Gastroenterol. 2008;42:875–9. - Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with
ulcerative colitis. Am J Gastroenterol. 2010;105:1430–6. - Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from inflix-
imab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007;44:312–7. - Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, out-
comes and optimal timing for second-line therapy. Gut. 2008;57:331–8. - Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multi-
center study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–91. - Falaiye TO, Mitchell KR, Lu Z, et al. Outcomes following infliximab therapy for pediatric
patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr.
2014;58:213–9. - Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for
children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391–9.
e1. - Adedokun OJ, Xu Z, Padgett L, et al. Pharmacokinetics of infliximab in children with
moderate- to-severe ulcerative colitis: results from a randomized, multicenter, open-label,
phase 3 study. Inflamm Bowel Dis. 2013;19:2753–62. - Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel
disease. Inflamm Bowel Dis. 2008;14:1683–7. - Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L. Safety and efficacy of adalimumab in
pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;47:19–25. - Cozijnsen M, Duif V, Kokke F, et al. Adalimumab therapy in children with Crohn disease
previously treated with infliximab. J Pediatr Gastroenterol Nutr. 2015;60:205–10.
S. Patel and J. Strople